Form 4: Apellis General Counsel Sells Shares for Tax Withholding

Apellis Pharmaceuticals' General Counsel, David O. Watson, sold 5,780 shares of common stock to cover tax withholding obligations related to restricted stock units.

Summary

• David O. Watson, General Counsel of Apellis Pharmaceuticals, Inc., reported a transaction involving the company's common stock.
• On January 13, 2026, Watson disposed of 5,780 shares of Apellis common stock.
• The shares were sold at a price of $22.1872 per share.
• The purpose of the sale was to cover tax withholding obligations associated with Restricted Stock Units (RSUs) that were released on January 12, 2026.
• Following this transaction, Watson directly beneficially owns 98,838 shares.
• Additionally, Watson indirectly beneficially owns 10,000 shares through a custodial account for minor children and 50,136 shares through The David O. Watson Irrevocable Trust of 2023, though he disclaims beneficial ownership over the trust shares except for his pecuniary interest.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The transaction is a routine insider sale for tax withholding purposes, executed under a 10b5-1 plan. It is neutral to slightly positive as it indicates a pre-planned, non-discretionary event, but it still represents a reduction in direct insider ownership.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale not based on new material non-public information.
• The sale was for tax withholding purposes, which is a common and routine event for executives receiving equity compensation.

Negatives

• An insider sale, even for tax purposes, reduces the insider's direct equity stake in the company.

Future Outlook

No future outlook or guidance is provided in this Form 4 filing.

Industry Context

This is a routine insider transaction for tax purposes, common across all industries for executives with equity compensation. It does not provide specific industry context for Apellis Pharmaceuticals.

Comparison to Industry Standards

• Insider sales for tax withholding are standard practice across publicly traded companies when Restricted Stock Units (RSUs) vest or stock options are exercised.
• The use of a Rule 10b5-1 plan is a common corporate governance practice to allow insiders to sell shares without concerns of trading on material non-public information.

Corporate Governance

Related Party Transactions

• Indirect beneficial ownership includes 10,000 shares held in a custodial account for minor children.
• Indirect beneficial ownership includes 50,136 shares held by The David O. Watson Irrevocable Trust of 2023, for which the reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the reason (tax withholding) and the 10b5-1 plan mitigate concerns about negative sentiment regarding the company's prospects.

Key Dates

Recommendation

The filing details a routine insider transaction where the General Counsel sold shares to cover tax withholding on vested Restricted Stock Units, executed under a Rule 10b5-1 plan. This is a common and expected event for executives and does not signal any new material information about the company's prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing. A 'hold' recommendation is appropriate as this transaction is neutral in its implications for the company's fundamental value or future performance.

Keywords

Apellis Pharmaceuticals, APLS, Form 4, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, Equity Compensation, David O. Watson, General Counsel, Rule 10b5-1